|May 14, 2013
Contact: Whitney Ray
Phone: (850) 245-0150
TALLAHASSEE, Fla.–Attorney General Pam Bondi announced today that Florida has entered a $350 million national settlement with Ranbaxy Laboratories Limited and its subsidiaries resolving claims of drug adulteration. The settlement entered by all 50 states, the District of Columbia and the federal government resolves allegations that Ranbaxy knowingly manufactured, distributed and sold generic pharmaceutical products whose strength, purity and/or quality fell below the standards required by the Food and Drug Administration. The products consisted of 26 generic pharmaceuticals manufactured between 2003 and 2010 at two of Ranbaxy’s facilities in India. Florida will receive more than $3 million as a result of the settlement.
“Floridians deserve the peace of mind of knowing that the medicine they purchase at a pharmacy meets FDA standards. My Medicaid Fraud Control Unit will not allow Florida’s taxpayers to pick up the tab for pharmaceutical companies that manufacture, distribute, and sell adulterated pharmaceutical drugs,” stated Attorney General Pam Bondi.
To resolve the federal government’s concurrent criminal charges, Ranbaxy USA, a subsidiary, pleaded guilty to seven felony counts alleging violations of the U.S. Food, Drug, and Cosmetic Act and has agreed to pay $150 million dollars in criminal fines and forfeitures. Additionally, Ranbaxy entered into a consent decree in January 2012 with the federal government to address manufacturing practices and data integrity issues in the two Indian manufacturing plants at issue. These provisions include a wide range of requirements to correct its violations and to ensure that the violations do not occur again.
The following entities are listed in the settlement: Ranbaxy, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy Laboratories, Inc., Ohm Laboratories, Inc., and Ranbaxy USA, Inc. (collectively “Ranbaxy”). To view the settlement, follow this link: http://myfloridalegal.com/webfiles.nsf/WF/JMEE-97PQTB/$file/Ranbaxy.pdf